David M. Feldser

14.1k citations

42 papers · 11.1k indexed · 6 hit papers · h-index 27

Impact in

Cancer Research top 0.05%
- Cancer-related molecular mechanisms research
- Cancer, Hypoxia, and Metabolism
- MicroRNA in disease regulation
Molecular Biology top 0.5%
- RNA modifications and cancer
- RNA Research and Splicing
- Circular RNAs in diseases
- Epigenetics and DNA Methylation

Papers in

Aging 2
Cancer Research 17
- Cancer, Hypoxia, and Metabolism 7
- Cancer-related molecular mechanisms research 5

Co-authors: Tyler Jacks Gregg L. Semenza Carol W. Greider Ido Amit Eric S. Lander Mitchell Guttman Maite Huarte Manuel Garber
Journals: Nature (5 papers)Cell (4 papers)Nature Communications (3 papers)Proceedings of the National Academy of Sciences (3 papers)Cancer Research (2 papers)
Partner nations: United States Austria Japan

In The Last Decade

David M. Feldser

40 papers receiving 10.9k citations

Hit Papers

6 papers align trajectories log scale

Copper is an essential regulator of the autophagic kinases ULK1/2 to drive lung adenocarcinoma 2020 · 268 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2020 Nature Cell Biology
2010 Cell
2009 Nature
2003 PubMed
2000 PubMed
1999 PubMed

Peers

Countries citing papers authored by David M. Feldser

Since Specialization

Citations

This map shows the geographic impact of David M. Feldser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David M. Feldser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David M. Feldser more than expected).

Fields of papers citing papers by David M. Feldser

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David M. Feldser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David M. Feldser. The network helps show where David M. Feldser may publish in the future.

Co-authors

The 25 scholars most cited alongside David M. Feldser, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David M. Feldser Line = papers co-authored together David M. Feldser links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Characterizing the Clinical and Molecular Profile of SETD2-Mutated Lung Adenocarcinoma Cancers ·J.P.J. De Jong, Raj Thali, Anne Fourcade-Jourdain, Molly Kunkel, Mohammad Saad Farooq, Ю. С. Вихарева, Simon Chen, David M. Feldser, John C. Kucharczuk, Sunil Singhal	2025	0
2	Setd2 inactivation sensitizes lung adenocarcinoma to inhibitors of oxidative respiration and mTORC1 signaling Communications Biology ·David M. Walter, 志自岐康子, Katherine R. Doerig, Ramakrishnan Natesan, Henri Krier, A. Andrea Gudiel, Pam Jordan-Long, Torsten Kirstges, Douglas C. Wallace, Irfan A. Asangani, David M. Feldser	2023	7
3	p53 restoration in small cell lung cancer identifies a latent cyclophilin-dependent necrosis mechanism Nature Communications ·Torsten Kirstges, Qinglan Li, Javier Martinez Cuadrado, P. Blanco-Sarto, Eurys Rolant, 浩生島, Michelle Cicchini, A. Soja, 志自岐康子, Pam Jordan-Long, Katherine R. Doerig, Jinyang Li, Takahashi Mai, Д А Халикова, Ben Z. Stanger, Luca Busino, Maureen E. Murphy, Liling Wan, David M. Feldser	2023	8
4	Metastatic Competency and Tumor Spheroid Formation Are Independent Cell States Governed by RB in Lung Adenocarcinoma Cancer Research Communications ·Javier Martinez Cuadrado, Oscar Seminar, Felicio Karem Mileo, 志自岐康子, David M. Feldser	2023	1
5	LKB1 drives stasis and C/EBP-mediated reprogramming to an alveolar type II fate in lung cancer Nature Communications ·Christopher W. Murray, Jennifer J. Brady, Shruti Kutty, Hongchen Cai, Min K. Tsai, Sarah E. Pierce, Ran Cheng, János Demeter, David M. Feldser, Peter K. Jackson, David B. Shackelford, Monte M. Winslow	2022	12
6	LKB1 inactivation modulates chromatin accessibility to drive metastatic progression Nature Cell Biology ·Sarah E. Pierce, Jeffrey M. Granja, M. Ryan Corces, Jennifer J. Brady, Min K. Tsai, Valderês Aaparecida de Sousa, Rui Tang, Pauline Chu, David M. Feldser, Howard Y. Chang, Michael C. Bassik, William J. Greenleaf, Monte M. Winslow	2021	34
7	RB depletion is required for the continuous growth of tumors initiated by loss of RB PLoS Genetics ·Lucie Jardot, Julia Arand, Dayong Wang, Alexandros P. Drainas, Yan Ting Shue, Myung Chang Lee, Shuyuan Zhang, David M. Walter, Andrea C. Chaikovsky, David M. Feldser, Hannes Vogel, Lukas E. Dow, Jan M. Skotheim, Julien Sage	2021	5
8	Type 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis The Journal of Experimental Medicine ·Jeffrey H. Lin, Austin P. Huffman, Max M. Wattenberg, David M. Walter, Erica L. Carpenter, David M. Feldser, Gregory L. Beatty, Emma E. Furth, Robert H. Vonderheide	2020	127
9	Blocking EGFR palmitoylation suppresses PI3K signaling and mutant KRAS lung tumorigenesis Science Signaling ·Akriti Kharbanda, David M. Walter, A. Andrea Gudiel, Nancy Schek, David M. Feldser, Eric S. Witze	2020	66
10	Reactivation of dormant tumor cells by modified lipids derived from stress-activated neutrophils Science Translational Medicine ·Michela Perego, Vladimir A. Tyurin, Yulia Y. Tyurina, Hirohiko Nakae, Timothy Nacarelli, Cindy Lin, Yulia Nefedova, Andrew V. Kossenkov, Qin Liu, Alexis Morvan, Harvey I. Pass, Johannes Roth, Thomas Vogl, David M. Feldser, Rugang Zhang, Valerian E. Kagan, Dmitry I. Gabrilovich	2020	146
11	Copper is an essential regulator of the autophagic kinases ULK1/2 to drive lung adenocarcinoma Nature Cell Biology ·Tiffany Tsang, Jessica M. Posimo, A. Andrea Gudiel, Michelle Cicchini, David M. Feldser, Donita C. Brady Hit paper breakdown →	2020	268
12	Natural killer cells limit the clearance of senescent lung adenocarcinoma cells Oncogenesis ·Kate L. Stokes, Virna Cortez‐Retamozo, Torsten Kirstges, Andrew Pu, Habip Eser Akkaya, Michelle Cicchini, Mikäel J. Pittet, David M. Feldser	2019	16
13	Systematic In Vivo Inactivation of Chromatin-Regulating Enzymes Identifies Setd2 as a Potent Tumor Suppressor in Lung Adenocarcinoma Cancer Research ·David M. Walter, Catalina Cerquera Arbeláez, Elizabeth L. Buza, John W. Tobias, Charuhas Deshpande, A. Andrea Gudiel, Caroline Kim-Kiselak, Michelle Cicchini, Travis J. Yates, David M. Feldser	2017	102
14	Recombinase-based conditional and reversible gene regulation via XTR alleles Nature Communications ·Habip Eser Akkaya, Sarah E. Taylor, Travis J. Yates, Michelle Cicchini, Andrew Pu, Christopher R. Cashman, Aurora A. Burds, Monte M. Winslow, Tyler Jacks, David M. Feldser	2015	24
15	Response and Resistance to NF-κB Inhibitors in Mouse Models of Lung Adenocarcinoma Cancer Discovery ·Wen Xue, Etienne Meylan, Trudy G. Oliver, David M. Feldser, Monte M. Winslow, Roderick Bronson, Tyler Jacks	2011	109
16	Suppression of lung adenocarcinoma progression by Nkx2-1 Nature ·Monte M. Winslow, Talya L. Dayton, Roel G.W. Verhaak, Caroline Kim-Kiselak, Eric L. Snyder, David M. Feldser, Diana Hubbard, Michel DuPage, Charles A. Whittaker, Sebastian Hoersch, Stephanie Yoon, Denise Crowley, Roderick T. Bronson, Derek Y. Chiang, Matthew Meyerson, Tyler Jacks	2011	317
17	Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma Nature ·Etienne Meylan, (unknown), David M. Feldser, О. М. Умаров, 秀樹千本, Chensi Ouyang, Tyler Jacks	2009	58
18	Hypoxia, HIF-1, and the Pathophysiologi of Common Human Diseases Kluwer Academic Publishers eBooks ·Gregg L. Semenza, Faton Agani, David M. Feldser, Roman Oros, Lori E. Kotch, Erik Laughner, Aimee Y. Yu	2006	159
19	Short Telomeres, even in the Presence of Telomerase, Limit Tissue Renewal Capacity Cell ·Ling-Yang Hao, Mary Armanios, Margaret A. Strong, Baktiar Karim, David M. Feldser, David L. Huso, Carol W. Greider	2005	235
20	Oncogenic levels of mitogen-activated protein kinase (MAPK) signaling of the dinucleotide KRAS2 mutations G12F and GG12-13VC Human Mutation ·David M. Feldser, Scott E. Kern	2001	4

About David M. Feldser

David M. Feldser is a scholar working on Aging, Cancer Research, Molecular Biology, Biotechnology and Oncology, having authored 42 papers that have together received 11.1k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (7 papers), Cancer, Hypoxia, and Metabolism (7 papers), RNA modifications and cancer (7 papers), Ubiquitin and proteasome pathways (5 papers), Telomeres, Telomerase, and Senescence (5 papers), Cancer-related molecular mechanisms research (5 papers), DNA Repair Mechanisms (4 papers) and CRISPR and Genetic Engineering (4 papers). The work is most often cited by research in Cancer Research (6.9k citations), Molecular Biology (8.1k citations), Aging (165 citations), Oncology (1.8k citations) and Endocrinology (222 citations). David M. Feldser has collaborated with scholars based in United States, Austria and Japan. Frequent co-authors include Tyler Jacks, Gregg L. Semenza, Carol W. Greider, Ido Amit, Eric S. Lander, Mitchell Guttman, Maite Huarte, Manuel Garber, Aviv Regev and Or Zuk. Their work appears in journals such as Nature, Cell, Nature Communications, Proceedings of the National Academy of Sciences and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact